Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 2M |
| Gross Profit | 0 | 0 | 0 | 0 | 753K |
| Operating Income | -2M | -1M | -3M | -829K | 207K |
| EBITDA | -1M | 0 | -2M | -7M | -544K |
| Net Income | -5M | -2M | -3M | -7M | 2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
-66.67%
Window
Jun 20, 2025 → Jun 15, 2026
Coverage: 251 bars · Jun 20, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
NovAccess Global Inc. (XSNX) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 66.7% across the available one-year price window (Jun 20, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -130.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -130.0%, free cash flow +30.9% with operating margin 0.0% and ROIC -0.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines XSNX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XSNX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XSNX Max Drawdown
-80.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XSNX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.6M
FY Net Income
$2.3M
+134.5% YoY
Free Cash Flow
-$8.8K
+90.5% YoY
Revenue Growth
+0.0%
EPS Growth
-130.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 2M |
| Gross Profit | 0 | 0 | 0 | 0 | 753K |
| Operating Income | -2M | -1M | -3M | -829K | 207K |
| EBITDA | -1M | 0 | -2M | -7M | -544K |
| Net Income | -5M | -2M | -3M | -7M | 2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21K | 64K | 181K | 178 | 8K |
| Total Assets | 62K | 125K | 208K | 178 | 215K |
| Total Liabilities | 8M | 5M | 4M | 4M | 2M |
| Shareholder Equity | -8M | -5M | -4M | -4M | -2M |
| Total Debt | 2M | 1M | 308K | 243K | 221K |
| Net Debt | 2M | 1M | 127K | 243K | 213K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7K
+93.0% YoY
Capital Expenditures
2K
Free Cash Flow
9K
+90.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
76.6%
Debt / Equity
-0.28x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.